30 results found.

Metastatic Breast Cancer Clinical Trial using Cisplatin; Metronomic Cyclophosphamide

Centre Jean Perrin - Recruiting 18 years or older.
- .
Cisplatin; Metronomic Cyclophosphamide

Metastatic GPNMB Over-expressing Triple Negative Breast Cancer Clinical Trial using CDX-011; Capecitabine

Celldex Therapeutics - Recruiting 18 years or older.
- A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE)in Patients With Metastatic, GPNMB Over-Expressing, Triple Negative Breast Cancer. (The METRIC Study).
CDX-011; Capecitabine

Breast Tumor, Breast Cancer, Cancer of the Breast, Estrogen Recep Clinical Trial using nab-Paclitaxel 125 mg/m2 plus carboplatin AUC 2 in triple negative metastatic breast cancer (TNMBC) subjects; Carboplatin AUC 2; gemcitabine 1000 mg

Celgene Corporation - Recruiting 18 years or older.
- A Phase 2/3, Multi-center, Open-label, Randomized Study of Weekly Nab-paclitaxel in Combination With Gemcitabine or Carboplatin, Compared to the Combination of Gemcitabine and Carboplatin, as First-line Treatment in Female Subjects With ER, PgR, and HER2 Negative (Triple Negative) Metastatic Breast Cancer.
nab-Paclitaxel 125 mg/m2 plus carboplatin AUC 2 in triple negative metastatic breast cancer (TNMBC) subjects; Carboplatin AUC 2; gemcitabine 1000 mg

Solid Tumors, Triple-Negative Breast Cancer, Non Small Cell Lung Clinical Trial using CB-839

Calithera Biosciences, Inc - Recruiting 18 years or older.
- A Phase 1 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Glutaminase Inhibitor CB-839 in Patients With Advanced and/or Treatment-Refractory Solid Tumors.
CB-839

Breast Cancer, or Ovarian Cancer Clinical Trial using AZ2281; Carboplatin

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Phase I Study With an Expansion Cohort of the PARP Inhibitor AZD2281 Combined With Carboplatin in BRCA1/2 Familial Breast and Ovarian Cancer and Sporadic Triple Negative Breast and Ovarian Cancer.
AZ2281; Carboplatin

Breast Cancer, or Triple Negative Breast Cancer Clinical Trial using Everolimus

The Methodist Hospital System - Recruiting 18 years or older.
- Neoadjuvant Phase II Study Of Everolimus Plus Cisplatin In Triple Negative Breast Cancer Patients With Residual Disease After Standard Chemotherapy.
Everolimus

Advanced Castrate-resistant Prostate Cancer (CRPC);, Squamous Non Clinical Trial using AZD8186

AstraZeneca - Recruiting 18 years or older.
- A Phase I, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD8186 in Patients With Advanced Castrate-resistant Prostate Cancer (CRPC), Squamous Non-Small Cell Lung Cancer (sqNSCLC), Triple Negative Breast Cancer (TNBC) and Patients With Known PTEN-deficient Advanced Solid Malignancies, With Expansion to Assess the Pharmacodynamic Activity of AZD8186 Within Prospectively-validated PTEN Deficient Tumours.
AZD8186

Breast Cancer Metastatic Clinical Trial using PF-03084014; Docetaxel

Pfizer - Recruiting 18 years or older.
- Phase 1B Study Of Docetaxel + PF-03084014 In Metastatic Or Locally Recurrent/Advanced Triple Negative Breast Cancer.
PF-03084014; Docetaxel

Breast Cancer, HER-2 Positive Breast Cancer, or Triple Negative B Clinical Trial using ganetespib

Synta Pharmaceuticals Corp. - Recruiting 18 years or older.
- An Open Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib(STA-9090) Monotherapy in Women With Previously Untreated Metastatic HER2 Positive or Triple Negative Breast Cancer.
ganetespib

Estrogen Receptor Negative Breast Cancer, Human Epidermal Growth Clinical Trial using cisplatin; laboratory biomarker analysis; pharmacological study; dynamic contrast-enhanced MRI, diffusion-weighted MRI & chemical exchange saturation transfer MRI; GDC -0941

Vanderbilt-Ingram Cancer Center - Recruiting 18 years or older.
- A Phase Ib/II Trial of GDC-0941 (a PI3K Inhibitor) in Combination With Cisplatin in Patients With Androgen Receptor Negative Triple Negative Metastatic Breast Cancer.
cisplatin; laboratory biomarker analysis; pharmacological study; dynamic contrast-enhanced MRI, diffusion-weighted MRI & chemical exchange saturation transfer MRI; GDC -0941

Breast Cancer Clinical Trial using BKM120

Dana-Farber Cancer Institute - Recruiting 18 years or older.
- A Phase II Trial of BKM120 in Patients With Triple Negative Metastatic Breast Cancer.
BKM120

Ovarian Cancer, or Breast Cancer Clinical Trial using BKM120 and Olaparib

Dana-Farber Cancer Institute - Recruiting 18 years or older.
- Phase I Study of the Oral PI3kinase Inhibitor BKM120 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or Recurrent High Grade Serous Ovarian Cancer.
BKM120 and Olaparib

Recurrent Breast Cancer, or Metastatic Breast Cancer Clinical Trial using Ruxolitinib; Paclitaxel

Dana-Farber Cancer Institute - Recruiting 18 years or older.
- Phase II Study of Combination Ruxolitinib (INCB018242) With Preoperative Chemotherapy for Triple Negative Inflammatory Breast Cancer Following Completion of a Phase I Combination Study in Recurrent/Metastatic Breast Cancer.
Ruxolitinib; Paclitaxel

Triple Negative Breast Cancer Clinical Trial using Cisplatin; Paclitaxel; Pre- and Post-chemotherapy clinical diagnostic tissue

Dana-Farber Cancer Institute - Recruiting 18 years or older.
- A Randomized Phase II Study of Preoperative Cisplatin Versus Paclitaxel in Patients With Triple Negative Breast Cancer Without Germline BRCA Mutations: Evaluating the Homologous Recombination Deficiency (HRD) Biomarker.
Cisplatin; Paclitaxel; Pre- and Post-chemotherapy clinical diagnostic tissue

Melanoma, Breast Neoplasms, Lobular Carcinoma, Triple-negative Br Clinical Trial using LGK974

Novartis - Recruiting 18 years or older.
- A Phase I, Open-label, Dose Escalation Study of Oral LGK974 in Patients With Malignancies Dependent on Wnt Ligands.
LGK974

Breast Cancer Clinical Trial

Thomas Jefferson University - Recruiting 18 years or older.
- Tumor Suppressor Status as a Predictor of Chemotherapy Response in Triple Negative Breast Cancer..

Breast Cancer Clinical Trial using Carboplatin; 3D-RT or IMRT

New York University School of Medicine - Recruiting 18 years or older.
- Phase I-II Study of Concurrent Adjuvant Systemic Therapy and Accelerated Radiotherapy (Over 3 Weeks).
Carboplatin; 3D-RT or IMRT

Breast Cancer Clinical Trial using Paclitaxel + LCL161; paclitaxel

Novartis - Recruiting 18 years or older.
- A Phase II Multi-center, Open-label, Neoadjuvant, Randomized Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast Cancer.
Paclitaxel + LCL161; paclitaxel

Triple Negative Breast Cancer Clinical Trial using Veliparib; Carboplatin; Paclitaxel; Doxorubicin; Cyclophosphamide

AbbVie - Recruiting 18 years or older.
- A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study Evaluating Safety and Efficacy of the Addition of Veliparib Plus Carboplatin Versus the Addition of Carboplatin to Standard Neoadjuvant Chemotherapy Versus Standard Neoadjuvant Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer (TNBC).
Veliparib; Carboplatin; Paclitaxel; Doxorubicin; Cyclophosphamide

Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Ca Clinical Trial using Paclitaxel; Carboplatin; Doxorubicin; Cyclophosphamide; Veliparib

Thomas Jefferson University - Recruiting 18 years or older.
- An Adaptive, Randomized Phase II Trial to Determine Pathologic Complete Response With the Addition of Carboplatin With and Without Veliparib to Standard Chemotherapy in the Neoadjuvant Treatment of Triple-Negative Breast Cancer.
Paclitaxel; Carboplatin; Doxorubicin; Cyclophosphamide; Veliparib

Advanced, Androgen Receptor Positive Triple Negative Breast Cance Clinical Trial using Enzalutamide

Medivation, Inc. - Recruiting 18 years or older.
- A Phase 2, Single Arm, Open Label, Multicenter Study of the Clinical Activity and Safety of Enzalutamide in Patients With Advanced, Androgen Receptor Positive, Triple Negative Breast Cancer.
Enzalutamide

Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Ca Clinical Trial using veliparib; cisplatin; vinorelbine tartrate; laboratory biomarker analysis; pharmacological study

University of Washington - Recruiting 18 years or older.
- Phase I Study of ABT-888 in Combination With Cisplatin and Vinorelbine for Patients With Advanced Triple Negative Breast Cancer and/or BRCA-Mutation Associated Breast Cancer.
veliparib; cisplatin; vinorelbine tartrate; laboratory biomarker analysis; pharmacological study

Breast Cancer Clinical Trial using GSK1120212

UNC Lineberger Comprehensive Cancer Center - Recruiting 18 years or older.
- Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212.
GSK1120212

Breast Cancer Clinical Trial using BRCA1 BRCA2 PTEN PALB2 mutation

Institut Paoli-Calmettes - Recruiting 18 years or older.
- Triple Negative Breast Cancer: Study of Molecular and Genetic Factors.
BRCA1 BRCA2 PTEN PALB2 mutation

Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Ca Clinical Trial using dinaciclib; epirubicin hydrochloride; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase 1 Study With Dose Expansion of Dinaciclib (SCH 727965) in Combination With Epirubicin in Patients With Metastatic Triple Negative Breast Cancer.
dinaciclib; epirubicin hydrochloride; laboratory biomarker analysis

Metastatic Non-Small Cell Lung Cancer, Metastatic Colon Cancer, o Clinical Trial using CTLA-4 Antibody; Hypofractionated Radiotherapy

Western Regional Medical Center - Recruiting 18 years or older.
- A Pilot Study of Immunochemotherapy +/- Hypofractionated Radiation for Complete Response in Solid Tumors (I-CREST).
CTLA-4 Antibody; Hypofractionated Radiotherapy

Metastatic Breast Cancer Clinical Trial using Cisplatin/Capecitabine

Chinese Academy of Medical Sciences - Recruiting 18 years to 70 years.
- Phase II Study of Capecitabine and Cisplatin in Anthracycline and Taxanes-pretreated Metastatic Triple Negative Breast Cancer Patients.
Cisplatin/Capecitabine

Breast Cancer Clinical Trial using Doxorubicin / Cyclophosphamide / Paclitaxel / Carboplatin; Definitive Surgery; Radiotherapy

Leo W. Jenkins Cancer Center - Recruiting 18 years to 75 years.
- Phase II Trial of Neoadjuvant Metronomic Chemotherapy in Triple-Negative Breast Cancer.
Doxorubicin / Cyclophosphamide / Paclitaxel / Carboplatin; Definitive Surgery; Radiotherapy

Breast Neoplasms Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- BRCA1 and BRCA2 Mutations and Triple Negative Disease in Hispanic/Latino Breast Cancer Subjects.

Breast Cancer Clinical Trial using Fluorouracil/epirubicin/cyclophosphamide following Docetaxel; Docetaxel/capecitabine followed by XEC

China Breast Cancer Clinical Study Group - Recruiting 18 years to 70 years.
- A Prospective, Randomized, Open, Multi-center Phase III Clinical Study Comparing Efficacy and Safety of Sequential T-FEC and TX-XEC as Post-operative Adjuvant Chemotherapy Options for the Treatment of Triple-negative Breast Cancer.
Fluorouracil/epirubicin/cyclophosphamide following Docetaxel; Docetaxel/capecitabine followed by XEC